Short-term in vitro drug testing of mamma tumors: relation to estrogen and progesterone receptor levels, age, and proliferation rate.
The correlation between age, proliferation rate of tumors, estrogen and progesterone receptors, and in vitro chemosensitivity to Adriamycin was studied on 43 primary mamma tumors. From an univariate statistical analysis of the results, it appeared that sensitive tumors, unlike resistant tumors, have fewer estrogen receptors and show a higher proliferation rate. And in addition, they are blocked to a greater extent by Adriamycin. In both groups age and progesterone receptors were not significantly different. A multivariate statistical analysis showed that in the classification into sensitive and resistant tumors, the percentage remaining incorporation after addition of Adriamycin and the proliferation rate contributed 94 and 5%, respectively. The first variable was the best measure for in vitro chemosensitivity. The classification of the tumors with the aid of a discriminant function proved to be successful in 91% of all the cases. No significant difference was observed between the in vitro sensitivity to Adriamycin when patients were divided into two groups according to age (less than or equal to 50 and greater than 50 years; 64 and 45% sensitive, respectively). This indicates that all patients benefit from the treatment. It also appeared that 85% of the estrogen negative tumors were sensitive to Adriamycin. So a chemotherapeutic instead of a hormonal therapy has to be considered for all ages, particularly in the case of estrogen negative receptors.
Oude Elferink
R F
RF
Department of Clinical Chemistry and Haematology, St. Elisabeth Hospital, Tilburg, The Netherlands.
Majoor
J M
JM
Leijten
J F
JF
Goldschmidt
H M
HM
D000367:Age Factors; D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002455:Cell Division / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects
D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D004317:Doxorubicin